Sharlene Gill, Medical Oncologist and Medical Director of Staff Wellness and Engagement at BC Cancer, shared a post on X:
“FIGHT-302 – Tanios Bekaii-Saab
1L Pemigatinib vs gem/cis in FGFR2-rearranged advanced cholangiocarcinoma
Closed early d/t change in 1L SOC, n=167 (4563 screened, <4% positivity rate)
- – ORR 47% vs 15%
- – PFS 8.3m vs 6.8m
- – no diff in OS with 50% crossover (mOS 24.4m vs 25m)
Kudos for this effort
Simultaneous JCO ASCO publication.”
To which Ronan Hsieh, Assistant Professor and GI oncologist at the University of Washington, added:
“Given early closure, most likely pemigatinib will stay in 2L.
However, a similar PFS1 of experimental arm and PFS2 of control arm crossover solidifies that 2L pemigatinib will be similarly effective.”
